Source comparison
PL-14736 Same as BPC-157: Designation Comparison
The following table clarifies the relationship between PL-14736 and BPC-157 across key research and sourcing parameters. Amino Acid Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Identical sequence. Molecular structure is the same Molecul
This comparison does not assign a generated winner or score.
- The following table clarifies the relationship between PL-14736 and BPC-157 across key research and sourcing parameters.
- Amino Acid Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Identical sequence. Molecular structure is the same
- Molecular Weight
- 1419.53 Da
- No difference in mass spectrometry analysis
- Research Literature Volume
- 40+ published studies (1993–2020)
- Primarily patent filings and trial registrations post-2010
- BPC-157 dominates peer-reviewed literature
- Nomenclature Origin
- University of Zagreb designation (1990s)
- European patent and clinical trial identifier
- Administrative labeling difference, not chemical
- Synthesis Method
- Solid-phase peptide synthesis, HPLC purification
- No methodological difference in production
- Mechanism of Action
- VEGF upregulation, NO pathway modulation, angiogenesis
- Identical biological activity
- Typical Research Purity
- ≥98% via HPLC
- Same purity standard applies to both designations
- Clinical Trial Status
- Limited human trials, extensive preclinical data
- Same preclinical foundation, newer trial registrations
- No difference in clinical development stage